{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:54:53Z","timestamp":1781848493426,"version":"3.54.5"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To explore the efficacy and prognostic factors of surgical resection in patients with non-small cell lung cancer (NSCLC) and isolated pleural metastasis (M1a) after receiving individualized conversion therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 167 patients with non-small cell lung carcinoma (NSCLC) and isolated pleural metastasis (M1a) admitted to Beijing Chest Hospital, Capital Medical University, from January 2019 to December 2023. Based on genotyping results, targeted therapy or chemo-immunotherapy regimens were administered. After conversion therapy, a multidisciplinary team (MDT) assessed surgical feasibility. The primary endpoint following comprehensive treatment was overall survival (OS) and progression-free survival (PFS), secondary endpoints included Objective response rate (ORR) and disease control rate (DCR); incidence of postoperative complications and Recurrence status. Survival probabilities were estimated using the Kaplan\u2013Meier method, and independent prognostic factors were identified using the Cox proportional hazards regression model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median follow-up for all patients was 28.5\u202fmonths. In total, 167 patients (82.26%) underwent curative or cytoreductive surgery. The median OS was 22.6\u202fmonths (95%CI: 18.4\u201326.8), and the median PFS was 12.4\u202fmonths (95% CI: 9.2\u201315.6). The 1-year and 2-year survival rates were 89.7 and 42.1%, respectively. Multivariate analysis revealed that squamous cell carcinoma (vs. adenocarcinoma, HR\u202f=\u202f1.68,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.012), driver gene negativity (HR\u202f=\u202f1.61,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.024), SD as the response to conversion therapy (vs.PR\/CR, HR\u202f=\u202f1.82,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.006), N2 lymph node metastasis (HR\u202f=\u202f1.85,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.003), and non-R0 resection (HR\u202f=\u202f2.08,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.001) were independent risk factors for OS. The postoperative complication rate was 12.57% (21\/167); complications of Clavien-Dindo grade \u22653 occurred in 28.57% (6\/21) of patients. Perioperative death occurred in one patient.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Surgical resection after effective conversion therapy significantly improves long-term survival in patients with isolated pleural metastatic lung cancer. Histological subtype, molecular characteristics, and completeness of resection are key prognostic indicators. Clinically, surgical intervention should prioritize patients who demonstrate a favorable response to conversion therapy, achieve R0 resection, and harbor driver gene mutations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>http:\/\/www.chictr.org.cn\/<\/jats:ext-link>\n                      , identifier ChiCTR2200056791.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1859804","type":"journal-article","created":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:47:57Z","timestamp":1781848077000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic factors analysis of surgical resection after conversion therapy for isolated pleural metastatic lung cancer: a retrospective analysis"],"prefix":"10.3389","volume":"13","author":[{"given":"Huan-Wei","family":"Qu","sequence":"first","affiliation":[{"name":"Surgical Intensive Care Unit, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Han","family":"Liu","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Han","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Yue","family":"Liu","sequence":"additional","affiliation":[{"name":"Surgical Intensive Care Unit, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer","article-title":"Current knowledge of small cell lung cancer transformation from non-small cell lung cancer","volume":"94","author":"Giaccone","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"ezag050","DOI":"10.1093\/ejcts\/ezag050","article-title":"Effect of surgical resection on isolated pleural dissemination in patients with stage IV (M1a) non-small cell lung Cancer: analysis from a cohort-based registry and a population-based database","volume":"68","author":"Xu","year":"2026","journal-title":"Eur J Cardiothorac Surg"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"oyag009","DOI":"10.1093\/oncolo\/oyag009","article-title":"An FDA analysis of the association of tumor growth rate, overall survival, and progression-free survival in patients with metastatic non-small cell lung cancer","volume":"31","author":"Malinou","year":"2026","journal-title":"Oncologist"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1002\/ijc.29915","article-title":"Targeted therapies for treatment of non-small cell lung cancer--recent advances and future perspectives","volume":"138","author":"Minguet","year":"2016","journal-title":"Int J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"113516","DOI":"10.1016\/j.intimp","article-title":"Effect of immunotherapy or anti-angiogenesis therapy combined with chemotherapy for advanced triple-negative breast cancer: a real-world retrospective study","volume":"143","author":"Chen","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.5582\/bst.2023.01322","article-title":"Conversion therapy for initially unresectable hepatocellular carcinoma: current status and prospects","volume":"17","author":"Ma","year":"2024","journal-title":"Biosci Trends"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1080\/14656566.2023.2229728","article-title":"Recent updates in the use of pharmacological therapies for downstaging in patients with hepatocellular carcinoma","volume":"24","author":"Takamoto","year":"2023","journal-title":"Expert Opin Pharmacother"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.21037\/tlcr-2025-182","article-title":"Development and validation of a serum inflammatory biomarker-driven machine-learning model for prognostic stratification in surgical limited-stage small cell lung cancer","volume":"14","author":"Yao","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.21037\/tlcr-24-809","article-title":"Evaluating the tumor response assessment of modified-RECIST 1.1 in advance non-small cell lung cancer: a post-hoc analysis of 1,147 patients from the EAST-LC trial","volume":"14","author":"Chen","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1007\/s00210-025-04596-9","article-title":"EGFR-targeted tyrosine kinase inhibitors: advancements in cancer therapy","volume":"399","author":"Ali","year":"2026","journal-title":"Naunyn Schmiedeberg's Arch Pharmacol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1021\/acs.molpharmaceut.2c00792","article-title":"Recent advances in boosting EGFR tyrosine kinase inhibitors-based Cancer therapy","volume":"20","author":"Pan","year":"2023","journal-title":"Mol Pharm"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00432-018-2642-4","article-title":"Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients","volume":"144","author":"Rojk\u00f3","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"vlaf013","DOI":"10.1093\/immhor\/vlaf013","article-title":"Identification and characterization of tissue resident memory T cells in malignant pleural effusions associated with non-small cell lung cancer","volume":"9","author":"Tilsed","year":"2025","journal-title":"Immunohorizons"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e423","DOI":"10.1016\/j.cllc.2020.02.027","article-title":"Skip N2 metastasis in pulmonary adenocarcinoma: good prognosis similar to N1 disease","volume":"21","author":"Wang","year":"2020","journal-title":"Clin Lung Cancer"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1007\/s00330-023-09476-5","article-title":"Tumour-pleura relationship on CT is a risk factor for occult lymph node metastasis in peripheral clinical stageIA solid adenocarcinoma","volume":"33","author":"Zhang","year":"2023","journal-title":"Eur Radiol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"5038","DOI":"10.1245\/s10434-024-15279-9","article-title":"Pathological pleural invasion is a risk factor for late recurrence in long-term survivors of non-small cell lung Cancer after complete resection","volume":"31","author":"Kanzaki","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1016\/j.jtho.2025.08.005","article-title":"Tumor cell invasion of the external elastic Lamina designates visceral pleural invasion and predicts poorer patient outcomes in pulmonary nonmucinous invasive adenocarcinoma","volume":"20","author":"Yeh","year":"2025","journal-title":"Thorac Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1186\/s12885-024-13029-4","article-title":"Comprehensive analysis of surgical strategies and prognosis for non-small cell lung cancer with pleural metastasis detected intraoperatively","volume":"24","author":"Meng","year":"2024","journal-title":"BMC Cancer"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"981","DOI":"10.4143\/crt.2024.993","article-title":"Long-term survival outcomes of surgical resection for lung adenocarcinoma with intraoperatively diagnosed pleural metastasis: target treatment era","volume":"57","author":"Kwon","year":"2025","journal-title":"Cancer Res Treat"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1457612","DOI":"10.3389\/fimmu.2024.1457612","article-title":"Biomarkers of lymph node metastasis in esophageal cancer","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1186\/s12885-023-11745-x","article-title":"Neo-adjuvant chemotherapy plus immunotherapy in resectable N1\/N2 NSCLC","volume":"23","author":"Du","year":"2023","journal-title":"BMC Cancer"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1089\/lap.2024.0138","article-title":"Minimally invasive with maximal yield: a narrative review of current practices in mediastinal lymph node staging in non-small cell lung Cancer","volume":"34","author":"Rodriguez","year":"2024","journal-title":"J Laparoendosc Adv Surg Tech A"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"5051","DOI":"10.1245\/s10434-023-13465-9","article-title":"Nationwide impact of centralization, neoadjuvant therapy, minimally invasive surgery, and standardized pathology reporting on R0 resection and overall survival in Pancreatoduodenectomy for pancreatic Cancer","volume":"30","author":"Augustinus","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"109114","DOI":"10.1016\/j.surg.2024.109114","article-title":"Impact of resection margin status on recurrence and survival in patients with resectable, borderline resectable, and locally advanced pancreatic cancer","volume":"180","author":"Rompen","year":"2025","journal-title":"Surgery"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.athoracsur.2025.06.030","article-title":"Primary thoracic synovial sarcoma: results of treatment at a single institution","volume":"121","author":"Aizpuru","year":"2026","journal-title":"Ann Thorac Surg"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.3390\/nu15102340","article-title":"Positive association of serum vitamin B6 levels with intrapulmonary lymph node and\/or localized pleural metastases in non-small cell lung Cancer: a retrospective study","volume":"15","author":"Liu","year":"2023","journal-title":"Nutrients"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"116397","DOI":"10.1016\/j.bcp.2024.116397","article-title":"Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: impact on following anti-PD-1 treatments","volume":"226","author":"Fumarola","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.3390\/cancers15102749","article-title":"Breaking the invisible barriers: unleashing the full potential of immune checkpoint inhibitors in oncogene-driven lung adenocarcinoma","volume":"15","author":"Kwok","year":"2023","journal-title":"Cancers (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40257-024-00852-5","article-title":"Rapidly evolving pre-and post-surgical systemic treatment of melanoma","volume":"25","author":"Augustin","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"104193","DOI":"10.1016\/j.critrevonc.2023.104193","article-title":"Preoperative therapy in melanoma: evolving perspectives in clinical trials","volume":"193","author":"Kakish","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11912-023-01369-6","article-title":"Neoadjuvant therapy in melanoma: where are we now?","volume":"25","author":"Saad","year":"2023","journal-title":"Curr Oncol Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1859804\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T05:47:58Z","timestamp":1781848078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1859804\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,19]]},"references-count":31,"alternative-id":["10.3389\/fmed.2026.1859804"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1859804","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,19]]},"article-number":"1859804"}}